The concept of gene therapy arose decades ago, when researchers postulated that human diseases could be treated by using a technique to introduce foreign DNA to correct genetic defects and disease phenotypes. In recent years, advances in gene therapy have been documented in the treatment of genetic disorders, cancer, and neurodegenerative diseases. Inherited diseases such as retinitis pigmentosa are among a handful of ocular diseases that are amenable to gene therapy. The Seeker desires solutions that will both qualitatively and (semi-) quantitatively measure in vivo gene expression in human ocular tissues.
This Challenge requires only a written proposal.
Source: InnoCentive Challenge ID: 9933643
The number of clinical trials for gene therapy to treat ocular disorders is on the rise. Inherited diseases such as retinitis pigmentosa among others are thought to be good candidates for targeted treatment. Currently, there is no method in humans to determine the level or geographic location of transgene expression following administration of gene therapy for diseases of the eye, specifically the retina. The Seeker desires solutions that will both qualitatively and (semi-) quantitatively measure in vivo gene expression in human ocular tissues.
Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on June 20, 2015. Late submissions will not be considered.
This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker.
To receive an award, Solvers will not be required to transfer their exclusive IP rights to the Seeker. Instead, Solvers will grant to the Seeker a [更多]